Trial Profile
A Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis (PN)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Nemolizumab (Primary)
- Indications Prurigo nodularis; Pruritus
- Focus Therapeutic Use
- Sponsors Galderma
- 24 Aug 2023 Results assessing the validity of the 11-point peak pruritus numerical rating scale (PP NRS) as a single-item patient-reported outcome (PRO) measure for assessing itch severity in prurigo nodularis, published in the Dermatology and Therapy.
- 09 Aug 2023 Results assessing characterize changes in plasma protein biomarkers associated with clinical response to nemolizumab in patients with PN. published in the JAMA Dermatology
- 17 Jun 2023 Results evaluating the Sleep Disturbance Numerical Rating Scale (SD NRS) as a single-item PRO measure for quantifying sleep disturbance in PN, published in the Dermatology and Therapy